Safety of aromatase inhibitors in the adjuvant setting (Breast Cancer Research and Treatment (2007) 105, SUPPL. 1, DOI: 10.1007/s10549-007-9704-7);Safety of aromatase inhibitors in the adjuvant setting

Breast Cancer Research and Treatment

Volumn 105, Issue 1 SUPPL., 2007, Pages 75-89

  Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adjuvant therapy; Aromatase inhibitors; Early breast cancer; Letrozole; Safety

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; EXEMESTANE; GESTAGEN; GOSERELIN; LETROZOLE; PLACEBO; TAMOXIFEN; TOREMIFENE; VITAMIN D; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANGINA PECTORIS; ARTHRALGIA; BONE DENSITY; BONE DISEASE; BREAST CANCER; CLINICAL TRIAL; COMORBIDITY; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG SAFETY; DYSPAREUNIA; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; GYNECOLOGIC CARE; HEART INFARCTION; HIP FRACTURE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; ISCHEMIC HEART DISEASE; LONG TERM CARE; MONOTHERAPY; MUSCLE CRAMP; MYALGIA; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; URINARY TRACT INFECTION; URINE INCONTINENCE; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL DRYNESS; VAGINAL PRURITUS; VERTIGO; XEROSTOMIA;

EID: 34948880730     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9854-7     Document Type: Erratum

References (138)

1. Nolvadex Adjuvant Trial Organization (1983) Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet 1:257-261
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
3. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529-1542
4. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527-537
5. Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19:322-328
6. Meijer D, van Agthoven T, Bosma PT, Nooter K, Dorssers LC (2006) Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells. Mol Cancer Res 4:379-386
7. Fisher B, Dignam J, Bryant J, Wolmark N (2001) Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93:684-690
8. Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A; Breast International Group (BIG) 1-98 Collaborative Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757. Erratum in: N Engl J Med (2006) 354:2200
9. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS; ATAC Trialists' Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62
10. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262-1271
11. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup Exemestane Study (2007) Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 17(369):559-570
12. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J; ABCSG, the GABG (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455-462
13. Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P (2005) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23:5138-5147
14. Brodie A, Lu Q, Liu Y, Long B (1999) Aromatase inhibitors and their antitumor effects in model systems. Endocr Relat Cancer 6:205-210
15. Brodie AH, Jelovac D, Long B (2003) The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens. J Steroid Biochem Mol Biol 86:283-288
16. Dowsett M, Jones A, Johnston SR, Jacobs S, Trunet P, Smith IE (1995) In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1:1511-1515
17. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE (2002) Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer women evaluated in a randomized, cross-over study. J Clin Oncol 20:751-757
18. Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, Folkerd E, Cameron D, Dowsett M (2006) Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 24(18S):15s. Abstract 552
19. National Comprehensive Cancer Network Practice Guidelines in Oncology v.1.2007. Breast Cancer Version 1.2007. http://www.nccn.org/professionals/ physician_gls/PDF/breast.pdf. Cited 6 Mar 2007
20. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619-629
21. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ; Panel members (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569-1583
22. Theriault RL, Biermann JS, Brown E, Brufsky A, Demers L, Grewal RK, Guise T, Jackson R, McEnery K, Podoloff D, Ravdin P, Shapiro CL, Smith M, Van Poznak CH (2006) NCCN task force report: bone health and cancer care. J Natl Compr Canc Netw 4(Suppl 2):S1-S20
23. Siegelmann-Danieli N, Khandelwal V, Wood GC, Mainali R, Prichard J, Murphy TJ, Evans JF, Yumen O, Bernath AM (2006) Breast cancer in elderly women: outcome as affected by age, tumor features, co-morbidities, and treatment approach. Clin Breast Cancer 7:59-66
24. Nagel G, Rohrig B, Hoyer H, Wedding U, Katenkamp D (2003) A population-based study on variations in the use of adjuvant systemic therapy on postmenopausal patients with early stage breast cancer. J Cancer Res Clin Oncol 129:183-191
25. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285:885-892
26. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991
27. Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286:2815-2822
28. Sirola J, Kroger H, Honkanen R, Jurvelin JS, Sandini L, Tuppurainen MT, Saarikoski S; OSTPRE Study Group (2003) Factors affecting bone loss around menopause in women without HRT: a prospective study. Maturitas 45:159-167
29. Guthrie JR, Lehert P, Dennerstein L, Burger HG, Ebeling PR, Wark JD (2004) The relative effect of endogenous estradiol and androgens on menopausal bone loss: a longitudinal study. Osteoporos Int 15:881-886
30. Hanna K, Wong J, Patterson C, O'Neill S, Lyons-Wall P (2004) Phytoestrogen intake, excretion and markers of bone health in Australian women. Asia Pac J Clin Nutr 13(Suppl):S74
31. Devine A, Dick IM, Dhaliwal SS, Naheed R, Beilby J, Prince RL (2005) Prediction of incident osteoporotic fractures in elderly women using the free estradiol index. Osteoporos Int 16:216-221
32. Prince RL, Dick I, Devine A, Price RI, Gutteridge DH, Kerr D, Criddle A, Garcia-Webb P, St John A (1995) The effects of menopause and age on calcitropic hormones: a cross-sectional study of 655 healthy women aged 35 to 90. J Bone Miner Res 10:835-842
33. Brazier M, Kamel S, Maamer M, Agbomson F, Elesper I, Garabedian M, Desmet G, Sebert JL (1995) Markers of bone remodeling in the elderly subject: effect of vitamin D insufficiency and its correction. J Bone Miner Res 10:1753-1761
34. Chen Z, Maricic M, Pettinger M, Ritenbaugh C, Lopez AM, Barad DH, Gass M, Leboff MS, Bassford TL (2005) Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer. Cancer 104:1520-1530
35. Chen Z, Maricic M, Bassford TL, Pettinger M, Ritenbaugh C, Lopez AM, Barad DH, Gass M, Leboff MS (2005) Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med 165:552-558
36. Pederson L, Winding B, Foged NT, Spelsberg TC, Oursler MJ (1999) Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity. Cancer Res 59:5849-5855
37. Bruning PF, Pit MJ, de Jong-Bakker M, van den Ende A, Hart A, van Enk A (1990) Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 61:308-310
38. Boyce SP, Mincey AB, Duh M, Marynchenko M, Raut MK, Brandman J, Perez EA (2005) Risk of osteoporosis/osteopenia among women with breast cancer receiving anti-cancer therapy (ACT). J Clin Oncol 23(16S):44s. Abstract 665
39. Mincey BA, Duh MS, Thomas SK, Moyneur E, Marynchencko M, Boyce SP, Mallett D, Perez EA (2006) Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer 7:127-132
40. Zhou Z, Redaelli A, Johnell O, Willke RJ, Massimini G (2004) A retrospective analysis of health care costs for bone fractures in women with early-stage breast carcinoma. Cancer 100:507-517
41. Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S, Spector T (1999) A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 79:1179-1181
42. The Arimidex, Tamoxifen, Alone or in Combination Trialists' Group, Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J, Locker GY, Nabholtz JM (2006) Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7:633-643
43. Coleman RE, on behalf of the ATAC Trialists' Group (2006) Effect of anastrozole on bone mineral density: 5-year results from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial. J Clin Oncol 24(18S):5s. Abstract 511
44. Howell A, on behalf of the ATAC Trialists' Group (2003) Effect of anastrozole on bone mineral density: 2-year results of the 'arimidex' (anastrozole), tamoxifen, alone or in combination (ATAC) trial. Presented at the 26th Annual San Antonio Breast Cancer Symposium, 3-6 December 2003. Abstract 129
45. Howell A, on behalf of the ATAC Trialists' Group (2006) Analysis of fracture risk factors from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial: 5-year data. J Clin Oncol 24(18S):18s. Abstract 563
46. Buzdar A, on behalf of the ATAC Trialists' Group (2006) Clinical features of joint symptoms observed in the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial. J Clin Oncol 24(18S):15s. Abstract 551
47. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE (2006) Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing ≥ 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 24:3629-3635
48. Goss PE, Qi S, Josse RG, Pritzker KP, Mendes M, Hu H, Waldman SD, Grynpas MD (2004) The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 34:384-392
49. Martinetti A, Zilembo N, Ferrari L, Massimini G, Polli A, La Torre I, Giovanazzi R, Pozzi P, Bidoli P, De Candis D, Seregni E, Bombardieri E, Bajetta E (2003) Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: results from a randomised trial of exemestane vs megestrol acetate. Anticancer Res 23:3485-3491
50. Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G (2005) Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23:5126-5137
51. Lonning PE, Geisler J, Krag LE, Ottestad L, Risberg T, Hagen AI, Schlichting E, Di Salle E, Polli A, Paolini J (2005) Changes in bone metabolism after 2 years treatment with exemestane in postmenopausal women with early breast cancer at low risk: follow-up results of a randomized placebo-controlled study. J Clin Oncol 23(16S):11s. Abstract 531
52. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM; Intergroup Exemestane Study (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092. Erratum in: N Engl J Med (2004) 351:2461
53. Jones SE, Cantrell J, Vukelja S, Pippen SJ, O'Shaughnessy J, Blum JL, Brooks R, Mull S, Ilegbodu D, Asmar L (2005) The effect of tamoxifen (T) or exemestane (E) on bone mineral density (BMD) after 1 year of adjuvant treatment of postmenopausal women with early breast cancer. J Clin Oncol 23(16S):31S. Abstract 610
54. Gonnelli S, Cadirni A, Caffarelli C, Petrioli R, Montagnani A, Franci MB, Lucani B, Francini G, Nuti R (2007) Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone 40:205-210
55. Lønning P, Geisler J, Krag LE, Løkkevik E, Risberg T, Hagen AI, Schlichting E, Eide GE, Di Salle E (2006) Vitamin D deficiency: a threat to bone health in breast cancer patients during adjuvant treatment with aromatase inhibitors. J Clin Oncol 24(18S):16s. Abstract 554
56. McCloskey E, Hannon R, Lakner G, Clack G, Miyamoto A, Eastell R (2006) The letrozole (L), exemestane (E), and anastrozole (A) pharmacodynamics (LEAP) trial: a direct comparison of bone biochemical measurements between aromatase inhibitors (AIs) in healthy postmenopausal women. J Clin Oncol 24(18S):16s. Abstract 555
57. U.S. Preventive Services Task Force (2005) Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force. Ann Intern Med 142:855-860
58. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S; American Society of Clinical Oncology (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057
59. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC, Galid A, Mittlboeck M, Hausmaninger H, Jakesz R; Austrian Breast and Colorectal Cancer Study Group (2007) Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25:820-828
60. Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA (2007) Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25:829-836
61. Bundred N, Campbell I, Coleman R, DeBoer R, Eidtmann H, Frassolati A, Llomobart A, Monnier A, Neven P, Dias R (2006) Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZO-FAST study). Eur J Cancer Suppl 4:48. Abstract 12
62. Brufsky A (2006) Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. Semin Oncol 33(Suppl 7):S13-S17
63. Brufsky A, Dong M, Lunk K, Warsi G, Cobb P, Eisenberg P, Papish S, Lacerna L, Perez E (2006) Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET). Breast Cancer Res Treat 100(Suppl 1):S233. Abstract 5060
64. Herman DR, Ganz PA, Petersen L, Greendale GA (2005) Obesity and cardiovascular risk factors in younger breast cancer survivors: The Cancer and Menopause Study (CAMS). Breast Cancer Res Treat 93:13-23
65. Matthews KA, Wing RR, Kuller LH, Meilahn EN, Plantinga P (1994) Influence of the perimenopause on cardiovascular risk factors and symptoms of middle-aged healthy women. Arch Intern Med 154:2349-2355
66. Stevenson JC, Crook D, Godsland IF (1993) Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 98:83-90
67. Chang J, Powles TJ, Ashley SE, Gregory RK, Tidy VA, Treleaven JG, Singh R (1996) The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann Oncol 7:671-675
68. Mitsuyama S, Yanagida Y, Doihara H, Komaki K, Kusama M, Ikeda T, Kimura M, Sano M, Miyauchi K (2006) A multi-center study of the effects of toremifene (TOR) and anastrozole (ANA) on serum lipids and bone metabolism in postmenopausal patients with estrogen receptor (ER) positive breast cancer: interim report. J Clin Oncol 24(18S):39s. Abstract 645
69. Femara Prescribing Information (2005) Novartis
70. Francini G, Petrioli R, Montagnani A, Cadirni A, Campagna S, Francini E, Gonnelli S (2006) Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer 95:153-158
71. Wasan KM, Goss PE, Pritchard PH, Shepherd L, Palmer MJ, Liu S, Tu D, Ingle JN, Heath M, Deangelis D, Perez EA (2005) The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 16:707-715
72. McCloskey E, Eastell R, Lakner G, Miyamoto A, Clack G (2005) Initial results from the LEAP study: the first direct comparison of safety parameters between aromatase inhibitors in healthy postmenopausal women. Breast Cancer Res Treat 94(Suppl 1):S101. Abstract 2052
73. Franklin SS (2006) Hypertension in older people: part 1. J Clin Hypertens (Greenwich) 8:444-449
74. Franklin SS, Pio JR, Wong ND, Larson MG, Leip EP, Vasan RS, Levy D (2005) Predictors of new-onset diastolic and systolic hypertension: the Framingham Heart Study. Circulation 111:1121-1127
75. Franklin SS, Jacobs MJ, Wong ND, L'Italien GJ, Lapuerta P (2001) Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 37:869-874
76. Franklin SS, Gustin W 4th, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D (1997) Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 96:308-315
77. American Heart Association. (2007) Heart disease and stroke statistics-2007 update. American Heart Association, Dallas
78. Louwman WJ, Janssen-Heijnen ML, Houterman S, Voogd AC, van der Sangen MJ, Nieuwenhuijzen GA, Coebergh JW (2005) Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 41:779-785
79. Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D (2005) Comorbidity and survival disparities among black and white patients with breast cancer. JAMA 294:1765-1772
80. Coebergh JW, Janssen-Heijnen ML, Post PN, Razenberg PP (1999) Serious comorbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993-1996. J Clin Epidemiol 52:1131-1136
81. Nilsson G, Holmberg L, Garmo H, Terent A, Blomqvist C (2005) Increased incidence of stroke in women with breast cancer. Eur J Cancer 41:423-429
82. Geiger AM, Fischberg GM, Chen W, Bernstein L (2004) Stroke risk and tamoxifen therapy for breast cancer. J Natl Cancer Inst 96:1528-1536
83. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL (2005) Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 23:8597-8605
84. Fumoleau P, Roche H, Kerbrat P, Bonneterre J, Romestaing P, Fargeot P, Namer M, Monnier A, Montcuquet P, Goudier MJ, Luporsi E; French Adjuvant Study Group (2006) Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol 17:85-92
85. Darby S, McGale P, Peto R, Granath F, Hall P, Ekbom A (2003) Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90,000 Swedish women. BMJ 326:256-257
86. Paszat LF, Mackillop WJ, Groome PA, Schulze K, Holowaty E (1999) Mortality from myocardial infarction following postlumpectomy radiotherapy for breast cancer: a population-based study in Ontario, Canada. Int J Radiat Oncol Biol Phys 43:755-762
87. Giordano SH, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS (2005) Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 97:419-424
88. Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811-7819
89. Conti E, Marchese N, Andreotti F (2004) Favorable cardiac risk among elderly breast carcinoma survivors. Cancer 100:878-879
90. Bradbury BD, Lash TL, Kaye JA, Jick SS (2005) Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina. Cancer 103:1114-1121
91. Rutqvist LE, Mattsson A (1993) Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85:1398-1406
92. Nordenskjold B, Rosell J, Rutqvist LE, Malmstrom PO, Bergh J, Bengtsson NO, Hatschek T, Wallgren A, Carstensen J (2005) Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. J Natl Cancer Inst 97:1609-1610
93. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF (2003) Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 18:937-947
94. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ (1995) Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ 311:977-980
95. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T; ATAC Trialists' Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131-2139. Erratum in: Lancet (2002) 360:1520
96. Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I, Von Minckwitz G; on behalf of the German Adjuvant Breast Cancer Group (2006) Survival benefit of switching to anastrozole after 2 years' treatment with tamoxifen versus continued tamoxifen therapy: the ARNO 95 study. J Clin Oncol 24(18S):14s. Abstract 547
97. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25:486-492
98. Sourander L, Rajala T, Raiha I, Makinen J, Erkkola R, Helenius H (1998) Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 352:1965-1969. Erratum in: Lancet (1999) 353:330
99. Medicines and Healthcare Products Regulatory Agency (MHRA) Publication Assessment Report (2005) Femara 2.5 mg tablet. http://www.mhra.gov.uk/home/ groups/lunit1/documents/websiteresources/con2023055.pdf. Cited 13 Jul 2006
100. Chakravarti S, Collins WP, Forecast JD, Newton JR, Oram DH, Studd JW (1976) Hormonal profiles after the menopause. Br Med J 2:784-787
101. Hutton JD, Jacobs HS, Murray MAF, James VHT (1978) Relation between plasma esterone and estradiol and climacteric symptoms. Lancet 1:678-681
102. Barnabei VM, Cochrane BB, Aragaki AK, Nygaard I, Williams RS, McGovern PG, Young RL, Wells EC, O'Sullivan MJ, Chen B, Schenken R, Johnson SR; Women's Health Initiative Investigators (2005) Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 105(5 Pt 1):1063-1073
103. Guthrie JR, Taffe JR, Lehert P, Burger HG, Dennerstein L (2004) Association between hormonal changes at menopause and the risk of a coronary event: a longitudinal study. Menopause 11:315-322
104. Morales L, Neven P, Timmerman D, Christiaens MR, Vergote I, Van Limbergen E, Carbonez A, Van Huffel S, Ameye L, Paridaens R (2004) Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs 15:753-760
105. Avis NE, Crawford SL, McKinlay SM (1997) Psychosocial, behavioral, and health factors related to menopause symptomatology. Womens Health 3:103-120
106. Feldman BM, Voda A, Groseth E (1985) The prevalence of hot flash and associated variables among perimenopausal women. Res Nurs Health 8:261-268
107. Freedman RR (2005) Pathophysiology and treatment of menopausal hot flashes. Semin Reprod Med 23:117-125
108. Randolph JF Jr, Sowers M, Bondarenko I, Gold EB, Greendale GA, Bromberger JT, Brockwell SE, Matthews KA (2005) The relationship of longitudinal change in reproductive hormones and vasomotor symptoms during the menopausal transition. J Clin Endocrinol Metab 90:6106-6112
109. Larson B, Collins A, Landgren BM (1997) Urogenital and vasomotor symptoms in relation to menopausal status and the use of hormone replacement therapy (HRT) in healthy women during transition to menopause. Maturitas 28:99-105
110. Ohayon MM (2006) Severe hot flashes are associated with chronic insomnia. Arch Intern Med 166:1262-1268
111. Bachmann GA (2005) Menopausal vasomotor symptoms: a review of causes, effects and evidence-based treatment options. J Reprod Med 50:155-165
112. Kumari M, Stafford M, Marmot M (2005) The menopausal transition was associated in a prospective study with decreased health functioning in women who report menopausal symptoms. J Clin Epidemiol 58:719-727
113. Baker A, Simpson S, Dawson D (1997) Sleep disruption and mood changes associated with menopause. J Psychosom Res 43:359-369
114. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG (2000) A prospective population-based study of menopausal symptoms. Obstet Gynecol 96:351-358
115. Owens JF, Matthews KA (1998) Sleep disturbance in healthy middle-aged women. Maturitas 30:41-50
116. Staropoli CA, Flaws JA, Bush TL, Moulton AW (1998) Predictors of menopausal hot flashes. J Womens Health 7:1149-1155
117. Rosen RC, Taylor JF, Leiblum SR, Bachmann GA (1993) Prevalence of sexual dysfunction in women: results of a survey study of 329 women in an outpatient gynecological clinic. J Sex Marital Ther 19:171-188
118. Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A (2004) Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 22:4261-4271
119. Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S, Clack G, Coibion M, Bianco AR (2006) The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 21:545-553
120. Gerber B, Krause A, Reimer T, Mylonas I, Makovitzky J, Kundt G, Janni W (2006) Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology. Clin Cancer Res 12:1245-1250
121. Thomas RJ, Marshall CJ, Williams M, Walker LG (2006) Switching to adjuvant letrozole improves hot flushes, mood and quality of life in the tamoxifen intolerant subgroup. Ann Oncol 17(Suppl 9):ix93. Abstract 264P
122. Jones S, Vukelja S, Cantrell J, O' Shaughnessy J, Pippen J, Brooks R, Blum J, Canfield V, Chittoor S, Gore I, Mull S, Guo H, Asmar L (2003) A planned comparison of menopausal symptoms during year 1 in patients receiving either exemestane or tamoxifen in a double-blind adjuvant hormonal study. Presented at the 26th Annual San Antonio Breast Cancer Symposium, 3-6 December 2003. Abstract 141
123. Aromasin Prescribing Information (2005) Pfizer, Inc
124. Paganini-Hill A, Clark LJ (2000) Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 64:165-176
125. Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S (2004) Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 13:61-66
126. Shah S, Bell RJ, Savage G, Goldstat R, Papalia MA, Kulkarni J, Donath S, Davis SR (2006) Testosterone aromatization and cognition in women: a randomized, placebo-controlled trial. Menopause 13:600-608
127. Takei H, Suemasu K, Inoue K, Saito T, Okubo K, Koh J, Sato K, Tsuda H, Kurosumi M, Tabei T (2006) Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone-sensitive, operable, breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03). Eur J Cancer Suppl 4:154. Abstract 368
128. Hori Y, Akizuki M, Nishimura R (2006) Comparison of adverse effects on lipid metabolism of anastrozole with tamoxifen in the adjuvant setting for postmenopausal women with early breast cancer. Eur J Cancer Suppl 4:94. Abstract 172
129. Lønning PE, Paridaens R, Thurlimann B, Piscitelli G, di Salle E (1997) Exemestane experience in breast cancer treatment. J Steroid Biochem Mol Biol 61:151-155
130. Paridaens R, Thomas J, Wildiers J, Vermeiren P, Lobelle JP, di Salle E, Ornati G, Zurlo MG, Polli A, Lanzalone S, de Belder K (1998) Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study. Anticancer Drugs 9:675-683
131. Cella D, Fallowfield L, on behalf of the ATAC Trialists' Group (2005) Five-year quality of life (QOL) follow-up of adjuvant endocrine therapy for postmenopausal women in the Arimidex (A), Tamoxifen (T), Alone or in Combination (ATAC) Trial. J Clin Oncol 23(16S):23S. Abstract 577
132. Ohsumi S, Shimozuma K, Ohashi Y, Nishiuchi H, Aihara T, Takatsuka Y (2005) Health-related quality-of-life and psychological distress of breast cancer patients after surgery during phase III randomized trial comparing further tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1 to 4 years: N-SAS BC 03. Breast Cancer Res Treat 94(Suppl 1):S99. Abstract 2044
133. Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, Martino S, Muss HB (2005) Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23:6931-6940
134. Abetz L, Barghout V, Thomas S, Arbuckle R (2005) Letrozole did not worsen quality of life relative to placebo in postmenopausal women with early breast cancer: results from the US subjects of the MA-17 study. Breast Cancer Res Treat 94(Suppl 1):S100. Abstract 2047
135. Fallowfield LJ, Bliss JM, Porter LS, Price MH, Snowdon CF, Jones SE, Coombes RC, Hall E (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24:910-917
136. Houghton J, on behalf of the ATAC Trialists' Group (2005) Using anastrozole as initial adjuvant treatment prevents early recurrences and reduces adverse events: updated data from the ATAC ('Arimidex, Tamoxifen, Alone or in Combination') trial. J Clin Oncol 23(16S):24S. Abstract 582
137. Houghton J (2006). Initial adjuvant therapy with anastrozole (A) reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen (T) - data reported on behalf of the ATAC ('Arimidex, tamoxifen, alone or in combination') trialists' group. Ann Oncol 17(Suppl 9):ix94. Abstract 243PD
138. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802